Form: 8-K

Current report filing

October 26, 2017

Exhibit 99.1

 

LOGO  

 

For investors    For media
Agnes Lee    Alison Graves
O: 858-836-5971    O: 858-836-6789
investorrelations@resmed.com    news@resmed.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2018

Revenue increased 13% to $523.7 million; up 11% on a constant currency basis

GAAP diluted earnings per share of $0.60; non-GAAP diluted earnings per share of $0.66

Operating cash flow of $94.0 million in the first quarter

SAN DIEGO, October 26, 2017 – ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2017. Revenue for the quarter was $523.7 million, a 13 percent increase compared to the same period of the prior year.

“We started the fiscal year with strong 11 percent constant currency revenue growth led by our masks, software-as-a-service solutions, and devices,” said Mick Farrell, ResMed’s chief executive officer. “Our new masks have performed well around the world, device sales are solid, and operating profit returned to double-digit growth in the quarter.”

Farrell concluded, “We are achieving share gains with new product innovation and delivering sustainable operating profit growth. We continue to pioneer products, services and solutions that improve patient outcomes, create efficiencies for our homecare providers, and help physicians and payers better manage chronic disease and lower long-term healthcare costs.”

Analysis of first quarter results

First quarter revenue in the Americas, excluding Brightree, was $296.6 million, an 11 percent increase over the same period of the prior year. Brightree revenue for the first quarter was $38.1 million, an increase of 15 percent compared to the same period of the prior year. Revenue in combined EMEA and APAC was $189.0 million, an increase of 11 percent on a constant currency basis, compared to the same period of the prior year.

Gross margin in the first quarter was 58.4 percent, higher than the prior year’s quarter gross margin of 57.8 percent. The improvement in gross margin compared to prior year was due to manufacturing and procurement efficiencies and the prior year Astral field safety notification expenses, which were partially offset by declines in average selling prices.


Income from operations for the quarter was $112.6 million, a 20 percent increase compared with the quarter ended September 30, 2016. Non-GAAP income from operations for the quarter was $124.3 million, a 12 percent increase compared to the same period of the prior year.

Selling, general and administrative expenses were $143.9 million, a 12 percent increase over the same period in the prior year, or a 10 percent increase on a constant currency basis. SG&A expenses improved to 27.5 percent of revenue in the quarter, compared with 27.7 percent reported in the quarter ended September 30, 2016.    

Research and development expenses were $37.4 million, or 7.1 percent of revenue. R&D expenses increased by 9 percent compared with the same period last year, or a 6 percent increase on a constant currency basis.

Amortization of acquired intangible assets was $11.8 million during the quarter, which is consistent with the same period last year. Stock-based compensation costs incurred during the quarter of $11.9 million consisted of expenses associated with employee equity grants, and our employee stock purchase plan.

Net income for the quarter was $86.1 million, a 13 percent increase compared to the same period of the prior year. Non-GAAP net income was $94.1 million, a 7 percent increase compared to the prior year.

Non-GAAP measures adjust for amortization of acquired intangibles and the Astral battery field safety notification expenses.

GAAP diluted earnings per share for the quarter increased by 11 percent to $0.60. Non-GAAP diluted earnings per share of $0.66 were 6 percent higher compared with the same period of the prior year.

Cash flow from operations for the quarter was $94.0 million compared to net income in the current quarter of $86.1 million. During the quarter we paid $49.7 million in dividends and repaid $60.0 million of our outstanding debt.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.35 per share. The dividend will have a record date of November 9, 2017, payable on December 14, 2017. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 8, 2017 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 8, 2017 through November 9, 2017 inclusive.

Webcast details

ResMed will discuss its first quarter fiscal year 2018 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2018 earnings webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing 800-585-8367 (U.S.) and +1 416-621-4642 (outside U.S.) and entering a passcode of 93203758. The telephone replay will be available until November 9, 2017.


About ResMed

ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 4 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

– More –


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

 

     Three Months Ended  
     September 30,  
     2017     2016  

Net revenue

   $ 523,659     $ 465,450  

Cost of sales

     218,054       191,196  

Astral field safety notification expenses (1)

     —         5,070  
  

 

 

   

 

 

 

Gross profit

     305,605       269,184  
  

 

 

   

 

 

 

Operating expenses:

    

Selling, general and administrative

     143,849       128,851  

Research and development

     37,415       34,446  

Amortization of acquired intangible assets (1)

     11,783       11,741  
  

 

 

   

 

 

 

Total operating expenses

     193,047       175,038  
  

 

 

   

 

 

 

Income from operations (1)

     112,558       94,146  
  

 

 

   

 

 

 

Other income (expenses), net:

    

Interest income (expense), net

     (2,915     (2,493

Other, net

     (1,158     1,272  
  

 

 

   

 

 

 

Total other income (expenses), net

     (4,073     (1,221
  

 

 

   

 

 

 

Income before income taxes

     108,485       92,925  

Income taxes

     22,360       16,818  
  

 

 

   

 

 

 

Net income (1)

   $ 86,125     $ 76,107  
  

 

 

   

 

 

 

Basic earnings per share

   $ 0.61     $ 0.54  

Diluted earnings per share

   $ 0.60     $ 0.54  

Non-GAAP diluted earnings per share (1)

   $ 0.66     $ 0.62  

Basic shares outstanding

     142,247       140,785  

Diluted shares outstanding

     143,480       142,090  

 

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

– More –


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited - In thousands)

 

     September 30,     June 30,  
     2017     2017  

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 811,102     $ 821,935  

Accounts receivable, net

     431,354       450,530  

Inventories

     300,472       268,319  

Prepayments and other current assets

     115,018       103,219  
  

 

 

   

 

 

 

Total current assets

     1,657,946       1,644,003  
  

 

 

   

 

 

 

Property, plant and equipment, net

     400,795       394,241  

Goodwill

     1,072,298       1,064,874  

Other intangibles, net

     251,025       261,800  

Deferred income taxes and other non-current assets

     107,553       103,569  
  

 

 

   

 

 

 

Total non-current assets

     1,831,671       1,824,484  
  

 

 

   

 

 

 

Total assets

   $ 3,489,617     $ 3,468,487  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY:

    

Current liabilities:

    

Accounts payable

     85,082       92,763  

Accrued expenses

     179,228       186,295  

Deferred revenue

     53,294       51,918  

Income taxes payable

     33,981       29,150  
  

 

 

   

 

 

 

Total current liabilities

     351,585       360,126  
  

 

 

   

 

 

 

Non-current liabilities:

    

Deferred revenue

     55,692       53,235  

Deferred income taxes

     11,566       13,822  

Other long term liabilities

     2,375       2,427  

Long-term debt

     1,018,871       1,078,611  
  

 

 

   

 

 

 

Total non-current liabilities

     1,088,504       1,148,095  
  

 

 

   

 

 

 

Total liabilities

     1,440,089       1,508,221  
  

 

 

   

 

 

 

STOCKHOLDERS’ EQUITY:

    

Common stock

     569       569  

Additional paid-in capital

     1,395,576       1,379,130  

Retained earnings

     2,352,664       2,316,237  

Treasury stock

     (1,546,611     (1,546,611

Accumulated other comprehensive income

     (152,670     (189,059
  

 

 

   

 

 

 

Total stockholders’ equity

   $ 2,049,528     $ 1,960,266  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 3,489,617     $ 3,468,487  
  

 

 

   

 

 

 

– More –


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited - In thousands)

 

     Three Months Ended  
     September 30,  
     2017     2016  

Cash flows from operating activities:

    

Net income

   $ 86,125     $ 76,107  

Adjustment to reconcile net income to cash provided by operating activities:

    

Depreciation and amortization

     29,571       27,775  

Stock-based compensation costs

     11,948       12,049  

Impairment of cost-method investments

     962       —    

Changes in operating assets and liabilities, net of effect of acquisitions:

    

Accounts receivable, net

     23,317       36,207  

Inventories, net

     (26,942     (28,073

Prepaid expenses, net deferred income taxes and other current assets

     (15,408     (19,115

Accounts payable, accrued expenses and other

     (15,590     (18,707
  

 

 

   

 

 

 

Net cash provided by operating activities

     93,983       86,243  
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Purchases of property, plant and equipment

     (16,030     (14,560

Patent registration costs

     (2,242     (2,471

Business acquisitions, net of cash acquired

     —         (3,090

Investments in cost-method investments

     (3,225     (2,758

Proceeds / (Payments) on maturity of foreign currency contracts

     6,073       9,710  
  

 

 

   

 

 

 

Net cash used in investing activities

     (15,424     (13,169
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net

     3,615       6,330  

Proceeds from borrowings, net of borrowing costs

     50,000       25,000  

Repayment of borrowings

     (110,000     (25,000

Dividends paid

     (49,698     (46,378
  

 

 

   

 

 

 

Net cash (used in) / provided by financing activities

     (106,083     (40,048
  

 

 

   

 

 

 

Effect of exchange rate changes on cash

     16,691       17,198  
  

 

 

   

 

 

 

Net increase / (decrease) in cash and cash equivalents

     (10,833     50,224  

Cash and cash equivalents at beginning of period

     821,935       731,434  
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 811,102     $ 781,658  
  

 

 

   

 

 

 

– More –


Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)

The measure, “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended  
     September 30,  
     2017      2016  

GAAP income from operations

   $ 112,558      $ 94,146  

Astral battery field safety notification expenses (A)

     —          5,070  

Amortization of acquired intangible assets (A)

     11,783        11,741  
  

 

 

    

 

 

 

Non-GAAP income from operations

   $ 124,341      $ 110,957  
  

 

 

    

 

 

 

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended  
     September 30,  
     2017      2016  

GAAP net income

   $ 86,125      $ 76,107  

Astral battery field safety notification expenses (A)

     —          3,549  

Amortization of acquired intangible assets, net of tax (A)

     8,013        8,006  
  

 

 

    

 

 

 

Non-GAAP net income (A)

   $ 94,138      $ 87,662  
  

 

 

    

 

 

 

Diluted shares outstanding

     143,480        142,090  
  

 

 

    

 

 

 

GAAP diluted earnings per share

   $ 0.60      $ 0.54  
  

 

 

    

 

 

 

Non-GAAP diluted earnings per share (A)

   $ 0.66      $ 0.62  
  

 

 

    

 

 

 

 

(A) ResMed adjusts for the impact of the amortization of acquired intangible assets and Astral battery field safety notification expenses from their evaluation of ongoing operations and believes investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight in evaluating ResMed’s performance from core operations and provides consistent financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

– End –